Trial Profile
Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary) ; Influenza vaccine (Optaflu) (Primary) ; Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Therapeutic Use
- 26 Jul 2022 Status changed from active, no longer recruiting to completed.
- 10 Jul 2021 Results (N=727) Comparing of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines among Healthcare Personnel published in the Clinical Infectious Diseases
- 16 Sep 2019 Planned End Date changed from 30 Apr 2019 to 31 Jul 2020.